Emergent BioSolutions Announces Sale of Baltimore-Bayview Manufacturing Site to Syngene International
GAITHERSBURG, Md., March 10, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has entered into an agreement to sell its Baltimore-Bayview drug substance manufacturing facility to Syngene International, a leading global contract research, development, and manufacturing organization, for a total value of $36.5 million. The Bayview site includes manufacturing, laboratory, warehousing and office space, and is fitted with multiple monoclonal antibody (mAbs) manufacturing lines.
As part of the agreement, Emergent will retain the rights to secure manufacturing services and capacity at the facility for future growth and pandemic response production in collaboration with Syngene. Emergent continues to operate a streamlined manufacturing network, including facilities in Lansing, Michigan and Winnipeg, Manitoba, Canada capable of serving strategic partners and supporting large-scale projects.
'The sale of Bayview represents a continuation of our efforts to deliver on our multi-year transformation plan and creates a streamlined, customer-focused, leaner, more flexible organization that provides the capabilities to deliver our product demand today and into the future,' said Joe Papa, president and CEO of Emergent. 'Now in our turnaround phase, we see significant opportunities for Emergent's core products and future growth drivers that have the potential to protect and save countless lives.'
In March 2024, Emergent received a favorable inspection outcome, 'No Action Indicated' or NAI status classification from the U.S. Food and Drug Administration (FDA) for the Bayview site. Emergent remains committed to ensuring continued compliance with Current Good Manufacturing Practices (CGMP) requirements and delivering high-quality products for communities around the world.
Papa added, 'Thanks to the hard work and dedication of colleagues across Emergent, we have strengthened operational quality and compliance systems across our network to continue to uphold the highest standards of patient safety, quality, and compliance in our work every day.'
The agreement with Syngene International includes a transfer of assets and equipment associated with the Baltimore-Bayview facility. The sale is expected to close in the first quarter of 2025, subject to the satisfaction of customary closing conditions.
For Emergent, Truist served as financial advisor, and Covington & Burling LLP served as legal counsel in connection with this transaction.
About Emergent BioSolutions
At Emergent, our mission is to protect and save lives. For over 25 years, we've been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare communities around the world for today's health challenges and tomorrow's threats, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify.
Safe Harbor Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including statements regarding the expected timing for completion of the disposition of Emergent's Baltimore-Bayview facility, Emergent's ability to achieve the objectives of the disposition, including achieving improvement in cost structure and performance, and Emergent's future results, are forward-looking statements. We generally identify forward-looking statements by using words like 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'forecast,' 'future,' 'goal,' 'improve,' 'intend,' 'may,' 'plan,' 'position,' 'possible,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would,' and similar expressions or variations thereof, or the negative thereof, but these terms are not the exclusive means of identifying such statements. Forward-looking statements are based on our current intentions, beliefs and expectations regarding future events based on information that is currently available. We cannot guarantee that any forward-looking statements will be accurate. Readers should realize that if underlying assumptions prove inaccurate or if known or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Readers are, therefore, cautioned not to place undue reliance on any forward-looking statements. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, we do not undertake any obligation to update any forward-looking statement to reflect new information, events or circumstances.
There are a number of important factors that could cause Emergent's actual results to differ materially from those indicated by any forward-looking statements. Readers should consider this cautionary statement, as well as the risk factors and other disclosures included in our periodic reports filed with the U.S. Securities and Exchange Commission, when evaluating our forward-looking statements.
Investor Contact:
Richard S. Lindahl
Executive Vice President, CFO
Media Contact:
Assal Hellmer
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Nyanzaga Gold Project Technical Report
Perth, June 10, 2025 (GLOBE NEWSWIRE) -- PERSEUS RELEASES TECHNICAL REPORT FOR THE NYANZAGA GOLD PROJECT Perth, Western Australia/June 10, 2025/ Perseus Mining Limited (ASX/TSX: PRU) is pleased to announce the release of the Technical Report for its Nyanzaga Gold Project (NGP) in Tanzania. The Technical Report, with an effective date of April 28, 2025, was prepared in compliance with Canadian Securities Administrators' National Instrument 43-101 and is available on and The Report summarises the results of the updated Feasibility Study to demonstrate the technical and economic viability of the NGP and supports a decision to advance to development. Please refer to News Release dated April 28, 2025 'Perseus Mining proceeds with development of the Nyanzaga Gold Project' for a summary of the material information contained in the Nyanzaga Technical Report. This announcement was approved for release by the Managing Director & CEO, Jeff Quartermaine. ASX/TSX CODE: PRUCAPITAL STRUCTURE:Ordinary shares: 1,362,221,512Performance rights: 10,056,681REGISTERED OFFICE:Level 2437 Roberts RoadSubiaco WA 6008Telephone: +61 8 6144 DIRECTORS:Rick MenellNon-Executive ChairmanJeff QuartermaineManaging Director & CEO Amber BanfieldNon-Executive DirectorElissa CorneliusNon-Executive DirectorDan LougherNon-Executive DirectorJohn McGloinNon-Executive Director CONTACTS:Jeff QuartermaineManaging Director & FormanInvestor Relations+61 484 036 RyanMedia Relations+61 420 582
Yahoo
an hour ago
- Yahoo
Why ABM Industries Topped the Market Today
Not one, but two analysts upgraded their recommendations on the company. Both now believe investors should buy its shares. 10 stocks we like better than Abm Industries › ABM Industries (NYSE: ABM) stock kicked off the trading week on a high note Monday, closing more than 3.5% higher in price following two recommendation upgrades from analysts tracking the stock. That performance was more than good enough to eclipse the bellwether S&P 500 index, which essentially flatlined that day. Those pundit updates came one business day after ABM released its second quarter of fiscal 2025 earnings report. The company notched a minor beat on the consensus analyst estimate for revenue but missed slightly on that for profitability. Investors didn't greet this development warmly, and their immediate reaction as a group was to trade out of ABM's shares. The situation flipped on Monday, however, as the pair of pundits published new takes on the stock before market open. The first upgrade came from Baird's Andrew Wittman. He upgraded his recommendation on ABM to outperform (i.e., buy) from the previous neutral at a price target of $56 per share. According to reports, Wittman feels the sell-off was unjustified and leaves the stock attractively priced, especially since the company has been effective at securing new work. His peer Joshua Chan at UBS also became notably more bullish on ABM with a recommendation change to buy from neutral (in his case, tagging the stock with a $50 per share price target). According to reports, Chan was particularly encouraged by renewed growth in the company's core business and industry segment. Personally, I'd fall between those bearish investors selling off ABM stock Friday and the analysts upping their recommendations. Yes, the company has reported some encouraging developments of late, but it's neither a strongly growing business nor a high-yielding dividend payer. I'd probably look elsewhere for stocks with better potential. Before you buy stock in Abm Industries, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Abm Industries wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor's total average return is 792% — a market-crushing outperformance compared to 173% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Abm Industries. The Motley Fool has a disclosure policy. Why ABM Industries Topped the Market Today was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
2 hours ago
- Business Insider
EPR, MO, and BTI: The Dividend Kings Offering Sturdy Yields and Stock Price Gains
In today's market, dividend investors often face a tough choice: high-yield stocks that risk becoming yield traps due to poor performance, or growth stocks with solid returns but minimal income. However, a select group of dividend stocks is managing to offer the best of both worlds—strong yields and solid performance. Not only are these stocks the so-called 'Dividend Kings', but they've also provided rather decent stock price appreciation in recent months. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter EPR Properties (EPR), Altria (MO), and British American Tobacco (BTI) are three dividend stocks worth watching, each offering an attractive yield of over 6%. Unlike many high-yield plays driven by declining share prices, these names have delivered substantial gains over the past year, making them standouts in the current landscape. EPR Properties (NYSE:EPR) While quarterly dividends are appreciated, monthly dividends offer even greater appeal—and that's precisely what EPR Properties provides. The stock currently offers an attractive 6.1% yield, nearly five times higher than the S&P 500 (SPX). Importantly, this yield isn't the result of a declining share price; EPR has been a strong performer, climbing 40% over the past 12 months. Despite this impressive rally, the stock remains reasonably valued, trading at just 11x forward funds from operations (FFO)—a key valuation metric for real estate investment trusts (REITs). As a firm, EPR specializes in owning and developing experiential properties across the U.S. Its portfolio includes a wide range of venues such as movie theaters, fitness centers, 'eat-and-play' destinations (like bowling alleys and golf entertainment venues such as TopGolf), amusement parks, water parks, and ski resorts. With 331 properties and over 200 tenants throughout the U.S. and Canada, EPR benefits from a broad and diversified income base. The company has paid a dividend for 27 consecutive years. However, it should be noted that while this is a monthly dividend payer, the company didn't pay a dividend for 15 months during 2020 and 2021 as it grappled with the effects of the COVID pandemic. While this is a concern worth being aware of, I don't think it's a cause for significant worry going forward as the pandemic and the lockdowns presented an extreme, unprecedented scenario for all businesses to deal with, especially ones like EPR that own experiential properties that require people to be out and about to be successful. Since resuming dividend payouts in July 2021, EPR has been paying these monthly dividends consistently and incrementally increasing the payouts over time. I'm bullish on this unique REIT based on its strong momentum over the past year, inexpensive valuation, 6%+ dividend yield, and attractive monthly payout schedule, making it a strong option for income investors. Is EPR a Good Stock to Buy? EPR earns a Hold consensus rating based on three Buys, five Holds, and two Sell ratings assigned in the past three months. The average EPR stock price target of $54.75 implies ~3% downside potential from current levels. Altria (NYSE:MO) Unlike EPR, Altria Group—the parent company of Marlboro cigarettes in the U.S., as well as electronic cigarette brand NJOY, and on! nicotine pouches—doesn't pay a monthly dividend. Instead, it follows the more traditional quarterly schedule. However, it makes up for that with an even higher yield of 6.8%, surpassing EPR's payout. And importantly, this yield isn't the result of weak performance—Altria shares have climbed ~27% over the past year. Beyond its generous yield, Altria offers exceptional dividend reliability. As a Dividend King, the company has increased its dividend for 55 consecutive years—a testament to its long-term commitment to shareholders. Altria is also returning capital through share buybacks. In Q1 2025, the company repurchased $326 million worth of stock, leaving $674 million remaining under its current authorization, which it aims to complete by the end of the year. Shares of Altria are also cheap, trading at just 11x earnings. This represents a significant discount to the broader market as the S&P 500 currently trades at roughly 21x. While tobacco companies are rarely associated with high growth, it's important to note that Altria is not a business in decline. The company is projecting steady, if modest, earnings per share growth of 2–5% for 2025. Notably, Altria is seeing strong momentum in its smokeless products segment—its on! nicotine pouches registered 18% year-over-year shipment growth in the most recent quarter, signaling a fruitful long-term market offering. I remain bullish on Altria, driven by its nearly 7% dividend yield, its remarkable track record of consistent dividend growth, and its attractive, undemanding valuation. Is Altria Group a Buy, Sell, or Hold? MO earns a Hold consensus rating based on three Buys, three Holds, and two Sell ratings assigned in the past three months. MO's average stock price target of $56.86 implies ~4% downside potential from current levels over the coming year. British American Tobacco (NYSE:BTI) Like Altria, British American Tobacco is a global leader in tobacco and nicotine products, delivering impressive returns—shares are up ~55% over the past 12 months. The company owns iconic cigarette brands, such as Lucky Strike, and markets Camel, American Spirit, and Newport in the U.S. Its portfolio also includes next-generation products, including Vuse vapor devices and Velo nicotine pouches. BTI currently offers an appealing dividend yield of 6.2%, paid quarterly. The company has a strong track record of 26 consecutive years of dividend growth on a GBP basis, though U.S. investors should note that payouts may vary in USD terms due to currency fluctuations. Valuation-wise, BTI appears attractively priced, trading at just 10.4x projected 2025 earnings—slightly below Altria's multiple and roughly half the valuation of the broader market. In addition to its dividend, BTI is actively returning capital to shareholders through stock buybacks. Following the partial sale of its stake in Indian conglomerate ITC, the company raised its 2025 buyback program to £1.1 billion. I'm bullish on BTI due to its strong yield, consistent dividend history, sizable share buyback program, and compelling valuation. What is the Price Target for BTI Stock? On Wall Street, BTI stock carries a Moderate Sell consensus rating based on coverage from just two analysts. According to Rashad Kawan from Morgan Stanley, BTI is rated a Sell with a price target of $35.50, indicating approximately 25% downside risk in BTI stock over the coming months. In his most recent research note, Kawan reaffirmed his Sell rating based on BTI's latest earnings release, published in February of this year. Meanwhile, John Eade from Argus Research issued a Hold rating on BTI at the turn of the year and has not changed his stance since. Three Strong Choices for Income Investors In today's market, it's rare to find stocks that offer both attractive dividend yields and strong performance, but EPR Properties, Altria, and British American Tobacco all manage to deliver on both fronts. I'm bullish on all three and consider them strong picks for income-focused investors. Each stock offers a dividend yield above 6%, trades at a reasonable valuation, and has posted impressive gains over the past year, making them far from typical yield traps. Among the three, my top picks are EPR and Altria. EPR stands out for its monthly dividend payments, differentiated business model, and diverse revenue streams. While both Altria and BTI are compelling options, I give the edge to Altria due to its exceptional track record of consistent dividend growth spanning more than five decades.
